(:PRAH)

Jun 28, 2021 06:07 pm ET
DT Midstream Set to Join S&P MidCap 400
NEW YORK, June 28, 2021 /PRNewswire/ -- DT Midstream Inc. (NYSE: DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective prior to the open on Friday, July 2. ICON plc (NASD: ICLR) is acquiring PRA Health Sciences in a deal expected to be completed soon pending final closing conditions. S&P 500 constituent DTE Energy Co. (NYSE: DTE) is spinning off DT Midstream in a transaction expected to be effective prior to the open on Thursday, July 1. Post spin-off, DTE Energy will remain in the S&P 500.  
Jun 23, 2021 08:01 am ET
Veradigm and PRA Health Sciences Partner to Create the Industry’s Leading EHR-Based Clinical Research Network
Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), and PRA Health Sciences, Inc. (NASDAQ: PRAH), one of the world’s leading global contract research organizations, announced today the creation of the industry’s leading electronic healthcare records-based clinical research network that reaches more than 25,000 physicians and 40 million patients across the United States.
May 28, 2021 03:13 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds BMTC, RBC, PRAH, and MNR Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th...
May 26, 2021 07:00 am ET
Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s...
May 13, 2021 04:02 pm ET
PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma
PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today an innovative tokenization solution using Synoma®, PRA’s proprietary technology that allows for the generation of enhanced evidence for drug development. PRA’s solution makes it possible to...
May 06, 2021 10:52 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates KSU, PMBC, PRAH, WRI; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Kansas City Southern (NYSE: KSU) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Apr 29, 2021 02:00 pm ET
PRA HEALTH SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PRA Health Sciences, Inc. - PRAH
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of PRA Health Sciences, Inc. (NasdaqGS: PRAH) to -ICON plc, (NasdaqGS: ICLR). Under the terms of the proposed transaction, shareholders of PRA will receive only $80 in cash and 0.4125 shares of ICON stock for each share of PRA that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Apr 28, 2021 04:01 pm ET
PRA Health Sciences, Inc. Reports First Quarter 2021 Results
PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended March 31, 2021. “I am delighted to report double-digit revenue and earnings growth for the first quarter of 2021,”...
Apr 21, 2021 04:02 pm ET
PRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeutics
PRA Health Sciences (NASDAQ: PRAH) announced today the expansion of its pharmacovigilance solution to offer full post-marketing services for authorized COVID-19 vaccines and therapeutics, including post-authorization safety studies (PASS) delivered...
Apr 14, 2021 12:42 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates COHR, BPFH, TPCO, PRAH; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Coherent, Inc. (NASDAQ: COHR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating...
Apr 13, 2021 04:02 pm ET
PRA Health Sciences selected by Maryland State Medical Society to supply remote patient monitoring and telehealth services
PRA Health Sciences (NASDAQ: PRAH) and the Maryland State Medical Society (MedChi) announced today that Care Innovations, a PRA Health Sciences company, was selected by MedChi to be a preferred provider of remote patient monitoring, telehealth, and...
Apr 07, 2021 04:01 pm ET
PRA’s remote patient monitoring platform selected by Merck KGaA, Darmstadt, Germany to work in combination with its human growth hormone treatment system
PRA Health Sciences (NASDAQ: PRAH) announced today that Merck KGaA, Darmstadt, Germany, known in the United States as EMD Serono, selected PRA’s remote patient monitoring platform to work in combination with its human growth hormone (HGH) treatment...
Apr 01, 2021 05:18 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of HWCC, BMTC, PRAH, and ATH Buyouts
Rigrodsky Law, P.A. announces that it is investigating: Houston Wire & Cable Company (NASDAQ GS: HWCC) regarding possible breaches of fiduciary duties and other violations of law related to Houston Wire’s agreement to be acquired by Omni Cable,...
Mar 24, 2021 07:00 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of SVBI, WIFI, PRAH, and STAY Buyouts
Rigrodsky Law, P.A. announces that it is investigating: Severn Bancorp, Inc. (NASDAQ GS: SVBI) regarding possible breaches of fiduciary duties and other violations of law related to Severn’s agreement to be acquired by Shore Bancshares, Inc....
Mar 22, 2021 04:01 pm ET
PRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical Programs
PRA Health Sciences (NASDAQ: PRAH) announced today the launch of its Patient-Centric Trial Development Toolkit, available now to clinical development sponsors focusing on rare diseases. Developed by PRA’s Center for Rare Diseases in collaboration...
Mar 19, 2021 03:10 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of CTB, ENBL, PRAH, and ATH Buyouts
Rigrodsky Law, P.A. announces that it is investigating: Cooper Tire & Rubber Company (NYSE: CTB) regarding possible breaches of fiduciary duties and other violations of law related to Cooper’s agreement to be acquired by The Goodyear Tire &...
Mar 16, 2021 10:31 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRAH, PRSP, FLIR, HMSY; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: PRA Health Sciences, Inc. (NASDAQ: PRAH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Mar 08, 2021 01:39 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates WIFI, PRAH, PAND, CTB; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Boingo Wireless, Inc. (NASDAQ: WIFI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Mar 04, 2021 05:40 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Buyout Investigation
Rigrodsky Law, P.A. announces that it is investigating: Pandion Therapeutics, Inc. (NASDAQ GS: PAND) regarding possible breaches of fiduciary duties and other violations of law related to Pandion’s agreement to be acquired by Merck & Co., Inc....
Mar 01, 2021 07:32 pm ET
PRA HEALTH SCIENCES INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PRA Health Sciences, Inc. - PRAH
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of PRA Health Sciences, Inc. (NasdaqGS: PRAH) to -ICON plc, (NasdaqGS: ICLR). Under the terms of the proposed transaction, shareholders of PRA will receive only $80 in cash and 0.4125 shares of ICON stock for each share of PRA that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Mar 01, 2021 08:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates PAND, PRAH, FFG, CTB; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Pandion Therapeutics, Inc. (NASDAQ: PAND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Feb 26, 2021 10:49 am ET
Moore Kuehn Encourages SFTW, PRAH, RTP, and PAND Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Feb 25, 2021 08:51 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - PAND, PRAH, AEGN, PTVCA, CRHM, CBLI, AKER
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Feb 24, 2021 01:44 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates PRA Health Sciences Inc.
NEW YORK, Feb. 24, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PRA Health Sciences Inc. ("PRAH" or the "Company") (NASDAQ: PRAH) in connection with the proposed cash-and-stock acquisition of the Company by ICON plc (NASDAQ GS: "ICLR").  Under the terms of the merger agreement, PRAH shareholders will receive $80.00 in cash and 0.4125 shares of stock for each share of PRAH common stock that they own, representing per-share merger consideration of approximately $166.05 based upon ICLR's February
Feb 24, 2021 01:09 pm ET
Shareholder Alert: Ademi LLP Investigates whether PRA Health Sciences, Inc. has obtained a Fair Price in its transaction with Icon
MILWAUKEE, Feb. 24, 2021 /PRNewswire/ -- Ademi LLP is investigating PRA Health (NASDAQ: PRAH) for possible breaches of fiduciary duty and other violations of law in its transaction with Icon.
Feb 24, 2021 12:09 pm ET
PRA HEALTH SCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRAH and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of PRA Health Sciences, Inc. (NASDAQ: PRAH) breached their fiduciary duties or violated the federal...
Feb 24, 2021 11:20 am ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of PRA Health Sciences, Inc. Buyout
Rigrodsky Law, P.A. announces that it is investigating PRA Health Sciences, Inc. (“PRA”) (NASDAQ GS: PRAH) regarding possible breaches of fiduciary duties and other violations of law related to PRA’s agreement to be acquired by ICON plc (“ICON”)...
Feb 24, 2021 10:48 am ET
PRA Health Sciences Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of PRA Health Sciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the F
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PRA Health Sciences, Inc. (NASDAQ: PRAH) to ICON plc is fair to PRA Health shareholders. Under the terms of the transaction, PRA Health shareholders will receive $80.00 in cash and 0.4125 shares of ICON stock for each PRA Health share that they own.
Feb 24, 2021 09:43 am ET
(PRAH): Johnson Fistel Investigates the Proposed Sale of PRA Health; Are Shareholders Getting a Fair Deal?
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of PRA Health Sciences, Inc. ("PRA" or the "Company") (NASDAQ: PRAH) breached their fiduciary duties in connection with the proposed sale of the Company to ICON plc, (NASDAQ: ICLR), ("ICON").  
Feb 24, 2021 06:04 am ET
PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2020 Results
PRA Health Sciences, Inc. (“PRA,” "we," "us," or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter and year ended December 31, 2020. "I am delighted to report fourth quarter revenue and earnings that significantly...
Feb 24, 2021 06:00 am ET
ICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research
ICON plc, (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, and government and public health organisations, today announced it has entered into a definitive agreement to acquire PRA Health Sciences, Inc. (NASDAQ: PRAH) in a cash and
Feb 04, 2021 01:00 pm ET
PRA Health Sciences to Report Fourth Quarter and Full Year 2020 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25, 2021. The Company will also host a conference call on Friday, February 26, 2021 at 9:00 a.m. (ET)...
Dec 17, 2020 04:02 pm ET
PRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provide at-home COVID-19 test capabilities
PRA Health Sciences (NASDAQ: PRAH) announced today the enhancement of its COVID-19 Monitoring Program with the addition of at-home COVID-19 testing capabilities. Enabled through a collaboration with PWNHealth and Fulgent Genetics (NASDAQ: FLGT),...
Nov 19, 2020 04:02 pm ET
PRA Health Sciences appoints senior FDA official to lead new Global Center of Excellence for Decentralized Clinical Trial Strategy
PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the appointment of Isaac Rodriguez-Chavez, PhD, MHS, MS, as Senior Vice President, Scientific and Clinical Affairs. He will lead the company’s Global Center of Excellence for Decentralized...
Nov 04, 2020 04:01 pm ET
PRA Health Sciences, Inc. Reports Third Quarter 2020 Results and Updates Full Year 2020 Guidance
PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended September 30, 2020. "I am very appreciative of the effort and focus of all of our employees despite the difficult...
Oct 07, 2020 05:09 pm ET
PRA Health Sciences to Report Third Quarter 2020 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its third quarter 2020 results after the market closes on Wednesday, November 4, 2020. The Company will also host a conference call on Thursday, November 5, 2020 at 9:00 a.m. (ET) to discuss...
Oct 06, 2020 04:02 pm ET
PRA Health Sciences selected by BARDA to be a member of its exclusive Clinical Studies Network
PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today it has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to be a member of its updated Clinical Studies Network (CSN). Under a Clinical Trial Planning and...
Sep 18, 2020 08:30 am ET
PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trials
PRA Health Sciences, Inc. (NASDAQ: PRAH) and Deep Lens, Inc., announced today a new strategic relationship to accelerate patient access and recruitment for oncology clinical trials. The relationship brings together best-in-class technologies that...
Sep 15, 2020 04:02 pm ET
PRA Health Sciences Announces Appointment of New Director
PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Glen Stettin, M.D. to the Board of Directors of the Company, effective September 14, 2020. “We are delighted that Glen will be joining our Board of Directors.  With his...
Aug 06, 2020 04:01 pm ET
PRA Health Sciences, Inc. Reports Second Quarter 2020 Results and Provides Third Quarter and Full Year 2020 Guidance
PRA Health Sciences, Inc. (“PRA,” “we,” “us” or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended June 30, 2020. “Considering the very difficult circumstances, I was delighted with our second quarter financial...
Jul 02, 2020 01:20 pm ET
PRA Health Sciences to Report Second Quarter 2020 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2020 results after the market closes on Thursday, August 6, 2020. The Company will also host a conference call on Friday, August 7, 2020 at 9:00 a.m. (ET) to discuss the...
Jun 18, 2020 08:05 am ET
PRA Health Sciences ready to navigate RACE Act requirements for pediatric oncology
Between 2007-2017, 78 novel adult cancer agents were approved by the U.S. Food and Drug Administration,1 but none of those drugs were researched to determine effectiveness for pediatric cancers. That is about to change on August 18 when the...
Jun 12, 2020 08:05 am ET
PRA Enhances COVID-19 Monitoring Program with Integration of Microsoft Healthcare Bot Service
PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service. Users of PRA’s Health Harmony digital platform who...
Apr 30, 2020 04:01 pm ET
PRA Health Sciences, Inc. Reports First Quarter 2020 Results, Withdraws Full Year 2020 Guidance Due to Uncertain COVID-19 Impact and Provides Second Quarter 2020 Guidance
PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the three months ended March 31, 2020. "During these unprecedented times, we have focused on the health and safety of employees...
Apr 13, 2020 04:35 pm ET
PRA Health Sciences to Report First Quarter 2020 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2020 results after the market closes on Thursday, April 30, 2020. The Company will also host a conference call on Friday, May 1, 2020 at 9:00 a.m. (ET) to discuss the results...
Apr 08, 2020 04:05 pm ET
Symphony Health to provide free access to new MetysTM COVID-19 Module for U.S. based life sciences industry during pandemic
PRA Health Sciences (NASDAQ: PRAH) announced today that Symphony Health, a PRA Health Sciences company, will make a 30-day license of its newly released MetysTM COVID-19 Module available to the U.S. life science industry at no charge. The...
Mar 24, 2020 04:05 pm ET
PRA Health Sciences expands remote clinical study support with its Mobile Health Platform during COVID-19 pandemic
As a response to the ongoing global COVID-19 pandemic, PRA Health Sciences announced today the expansion of its industry-leading Mobile Health Platform for remote clinical monitoring, adding several new capabilities that address sponsor needs for...
Mar 20, 2020 05:08 pm ET
PRA Health Sciences Launches COVID-19 Monitoring Program
PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals...
Mar 11, 2020 04:02 pm ET
Symphony Health Partners with Datavant for the Industry’s Deepest View of the Patient Journey
PRA Health Sciences (NASDAQ: PRAH) announced today a partnership between Symphony Health and Datavant that expands the breadth of data available for integration and allows life sciences companies to get the deepest and most holistic view of the...
Feb 20, 2020 04:01 pm ET
PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2019 Results and Provides First Quarter and Full Year 2020 Guidance
PRA Health Sciences, Inc. (“PRA” or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter and year ended December 31, 2019. "We are pleased with our financial results for the quarter and are delighted to have...
Feb 03, 2020 04:01 pm ET
PRA Health Sciences to Report Fourth Quarter 2019 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2019 results after the market closes on Thursday, February 20, 2020. The Company will also host a conference call on Friday, February 21, 2020 at 9:00 a.m. (ET)...
Oct 30, 2019 04:02 pm ET
PRA Health Sciences, Inc. Reports Third Quarter 2019 Results and Updates Full Year 2019 Guidance
PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended September 30, 2019. "Our third quarter financial results produced solid revenue growth and double digit earnings...
Oct 09, 2019 04:05 pm ET
PRA Health Sciences to Report Third Quarter 2019 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its third quarter 2019 results after the market closes on Wednesday, October 30, 2019. The Company will also host a conference call on Thursday, October 31, 2019 at 9:00 a.m. (ET) to discuss the...
Sep 18, 2019 08:00 am ET
PRA Health Sciences, Symphony Health Launch Metys(TM) National Market Measurement Tool
PRA Health Sciences (NASDAQ: PRAH) announced today the launch of Symphony Health’s new national market measurement tool – Metys™ (pronounced Met-IS), the only completely integrated, all-in-one market research solution available from a contract...
Sep 04, 2019 06:00 am ET
PRA Health Sciences, Inc. Announces Pricing of Secondary Offering and Concurrent Share Repurchase
PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced the pricing of the previously announced secondary offering of shares of its common stock.  KKR PRA Investors L.P. (the “Selling Stockholder”), has agreed to sell an aggregate...
Sep 03, 2019 05:59 pm ET
PRA Health Sciences, Inc. Announces $500 Million Share Repurchase Program
PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced that its Board of Directors (the “Board”) has authorized a $500 million share repurchase program, effective immediately.  Under the program, the Company is authorized to...
Sep 03, 2019 05:24 pm ET
PRA Health Sciences, Inc. Announces Secondary Offering and Concurrent Share Repurchase
PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced that KKR PRA Investors L.P. (the “Selling Stockholder”), intends to offer for sale in an underwritten secondary offering 6,666,684 shares of common stock of the Company...
Aug 19, 2019 10:18 am ET
PRA Health Sciences Announces Strategic Alliance between Symphony Health and Close-Up International
PRA Health Sciences (NASDAQ: PRAH) announced today that Symphony Health, the company’s data solutions division, has expanded its global data services by entering into a strategic partnership with Close-Up International, a leading Latin...
Jul 11, 2019 10:08 am ET
CORRECTING and REPLACING -- PRA Health Sciences to Report Second Quarter 2019 Earnings
In a release issued under the same headline on July 9, 2019 by PRA Health Sciences, Inc. (NASDAQ: PRAH), please note that in the second paragraph of the release, the conference call ID and replay ID should read "6295812" and not "1876878" as...
Jul 09, 2019 04:15 pm ET
PRA Health Sciences to Report Second Quarter 2019 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2019 results after the market closes on Wednesday, July 31, 2019. The Company will also host a conference call on Thursday, August 1, 2019 at 9:00 a.m. (ET) to discuss the...
May 14, 2019 07:00 am ET
PRA Health Sciences Earns Recognition, Industry Awards
PRA Health Sciences, Inc. is pleased to announce it has received an array of awards and recognition during the first months of 2019. On Saturday, May 4, PRA was recognized as the Clinical Research Company of the Year – the Americas by PharmaTimes....
May 01, 2019 04:00 pm ET
PRA Health Sciences, Inc. Reports First Quarter 2019 Results
PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the three months ended March 31, 2019. "The year is off to a solid start and I am delighted to report that our first quarter results...
Apr 11, 2019 08:10 am ET
Research Report Identifies Spirit Aerosystems, The Descartes Systems Group, Lantheus, Quanex Building Products, News Corporation, and PRA Health Sciences with Renewed Outlook — Fundamental Analysis, C
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Spirit Aerosystems Holdings, Inc. (NYSE:SPR), The Descartes Systems...
Apr 09, 2019 04:00 pm ET
PRA Health Sciences to Report First Quarter 2019 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2019 results after the market closes on Wednesday, May 1, 2019. The Company will also host a conference call on Thursday, May 2, 2019 at 9:00 a.m. (ET) to discuss the results...
Apr 08, 2019 09:00 am ET
PRA Health Sciences Receives CRO Leadership Awards
PRA Health Sciences, Inc. is pleased to announce it has won a 2019 CRO Leadership Award in the following categories: Capabilities (Overall, Big Pharma, Small Pharma)Compatibility (Overall, Big Pharma, Small Pharma)Expertise (Small...
Mar 07, 2019 01:58 pm ET
PRA Blue Bell Named 2019 Top Workplace by Philadelphia Inquirer
PRA Health Sciences is delighted to be included as the only CRO on the Philadelphia Inquirer’s list of Top Workplaces for 2019.  The best employers around the country are annually recognized for their commitment to developing and sustaining a...
Feb 27, 2019 05:21 pm ET
PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2018 Results and Provides First Quarter and Full Year 2019 Guidance
PRA Health Sciences, Inc. (“PRA” or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter and year ended December 31, 2018. "We are delighted to have closed out 2018 with another quarter of strong financial results,” said...
Feb 25, 2019 10:20 am ET
PRA Health Sciences and CISCRP Collaborate to Provide Clinical Trial Results Summaries to Patients and the Public
PRA Health Sciences and the non-profit Center for Information and Study on Clinical Research Participation (CISCRP) are pleased to announce that they are collaborating to prepare and deliver Trial Results Summaries to study volunteers. A key focus...
Feb 06, 2019 07:55 am ET
Analysis: Positioning to Benefit within Conagra Brands, National Retail Properties, PRA Health Sciences, Westinghouse Air Brake Technologies, YRC Worldwide, and Infinity Pharmaceuticals — Research Hig
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Conagra Brands Inc. (NYSE:CAG), National Retail Properties (NYSE:NNN),...
Feb 04, 2019 04:31 pm ET
PRA Health Sciences to Report Fourth Quarter 2018 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2018 results after the market closes on Wednesday, February 27, 2019. The Company will also host a conference call on Thursday, February 28, 2019 at 9:00 a.m....
Jan 16, 2019 08:30 am ET
Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais, M.D., J.D. to its board of directors. Dr. Grais brings a diverse and important set of...
Dec 13, 2018 09:00 am ET
Symphony Health Announces Availability of 340B Drug Discount Program Data
Symphony Health, a PRA Health Sciences company and a leading provider of data, cloud-based analytics and consulting solutions to life science companies and healthcare organizations, today announces the availability of 340B Drug Discount Program...
Nov 27, 2018 10:08 am ET
PRA Health Sciences Launches Pediatric Site Network
PRA Health Sciences (PRA) is pleased to announce the launch of its new Pediatric Site Network (PSN). PSN is a series of key pediatric research centers around the world which will allow PRA to improve pediatric clinical development and enhance...
Nov 06, 2018 08:10 am ET
New Research: Key Drivers of Growth for PRA Health Sciences, Newmont Mining, Hyster-Yale Materials Handling, MGP Ingredients, Noble Midstream Partners LP, and Principal Financial Group — Factors of In
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PRA Health Sciences, Inc. (NASDAQ:PRAH), Newmont Mining Corporation...
Oct 31, 2018 04:39 pm ET
PRA Health Sciences, Inc. Reports Third Quarter 2018 Results and Updates 2018 Guidance
PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended September 30, 2018. For the three months ended September 30, 2018, revenue was $717.6 million, which represents...
Oct 15, 2018 07:30 am ET
Consolidated Research: 2018 Summary Expectations for Lancaster Colony, Pioneer Natural Resources, Essex Property Trust, PRA Health Sciences, Pinnacle Entertainment, and Laredo Petroleum — Fundamental
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lancaster Colony Corporation (NASDAQ:LANC), Pioneer Natural Resources...
Sep 25, 2018 04:46 pm ET
PRA Health Sciences to Report Third Quarter 2018 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its third quarter results after the market closes on Wednesday, October 31, 2018. The Company will also host a conference call on Thursday, November 1, 2018 at 9:00 a.m. (ET) to discuss the...
Aug 09, 2018 08:10 am ET
New Research: Key Drivers of Growth for Tenet Healthcare, DDR, Newmont Mining, Tahoe Resources, PRA Health Sciences, and Arch Coal — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tenet Healthcare Corporation (NYSE:THC), DDR Corp. (NYSE:DDR), Newmont...
Aug 07, 2018 06:45 am ET
PRA Health Sciences, Inc. Announces Pricing of Secondary Offering of 6,500,000 Shares of Common Stock
PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced the pricing of the previously announced secondary offering of shares of its common stock.  An affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts Co. (the “Selling...
Aug 06, 2018 04:59 pm ET
PRA Health Sciences, Inc. Announces Secondary Offering of 6,500,000 Shares of Common Stock
PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced that an affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts Co. (the “Selling Stockholder”), intends to offer for sale in an underwritten secondary offering...
Aug 01, 2018 04:00 pm ET
PRA Health Sciences, Inc. Reports Second Quarter 2018 Results and Updates Full Year 2018 Guidance
PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended June 30, 2018. For the three months ended June 30, 2018, revenue was $722.8 million, which represents growth...
Jul 12, 2018 02:04 pm ET
PRA Health Sciences to Report Second Quarter 2018 Earnings
PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter results after the market closes on Wednesday, August 1, 2018. The Company will also host a conference call on Thursday, August 2, 2018 at 9:00 a.m. (ET) to discuss the results...
May 25, 2018 05:55 pm ET
ABIOMED Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, May 25, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600:
May 24, 2018 04:00 am ET
PRA Named International Clinical Research Company of the Year
PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. “This award celebrates...
May 08, 2018 07:30 am ET
Consolidated Research: 2018 Summary Expectations for The Mosaic, Newmont Mining, National Oilwell Varco, NxStage Medical, Public Service Enterprise Group, and PRA Health Sciences — Fundamental Analysi
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Mosaic Company (NYSE:MOS), Newmont Mining Corporation (NYSE:NEM),...
May 03, 2018 10:00 am ET
PRA Named Clinical Research Company of the Year and Makes the Forbes 2018 America’s Best Large Employers List
PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized as the Clinical Research Company of the Year—Americas by PharmaTimes. PRA received the award at a ceremony in Washington, DC. The company has won this award...
Apr 25, 2018 04:04 pm ET
PRA Health Sciences Announces Retirement of Chief Financial Officer and Promotion of Michael Bonello to CFO
RALEIGH, N.C., April 25, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced that Linda Baddour, Executive Vice President and Chief Financial Officer will retire from her position as CFO, effective May 1, 2018.  Ms. Baddour...
Apr 25, 2018 04:00 pm ET
PRA Health Sciences, Inc. Reports First Quarter 2018 Results
RALEIGH, N.C., April 25, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA” or the “Company”) (NASDAQ:PRAH) today reported financial results for the quarter ended March 31, 2018.
Apr 12, 2018 04:01 pm ET
PRA Health Sciences to Report First Quarter 2018 Earnings
RALEIGH, N.C., April 12, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2018 results after the market closes on Wednesday, April 25, 2018. The Company will also host a conference call on...
Mar 14, 2018 09:00 am ET
PRA Health Sciences Receives CRO Leadership Award
RALEIGH, N.C., March 14, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it has won a 2018 CRO Phase IV Leadership Award (Overall, Big Pharma). For the 2018 CRO Leadership Awards, Life Science...
Mar 06, 2018 10:00 am ET
PRA Health Sciences Named Best CRO in Asia
RALEIGH, N.C., March 06, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is honored to once again be named Best CRO in Asia. PRA received this recognition at the Phar-East Pharma and Biotech Festival (formally known as...
Mar 06, 2018 08:15 am ET
Report: Exploring Fundamental Drivers Behind Okta, Conduent, Innoviva, PRA Health Sciences, DDR, and Tenet Healthcare — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Okta, Inc. (NASDAQ:OKTA), Conduent Inc. (NYSE:CNDT),...
Feb 22, 2018 08:30 am ET
PRA Health Sciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / PRA Health Sciences, Inc. (NASDAQ: PRAH) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018 at 10:00 AM Eastern Time.
Feb 21, 2018 04:00 pm ET
PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2017 Results and Provides Q1 and FY 2018 Guidance
RALEIGH, N.C., Feb. 21, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA” or the “Company”) (NASDAQ:PRAH) today reported financial results for the quarter and year ended December 31, 2017.
Feb 12, 2018 10:00 am ET
PRA Health Sciences Partners with IMPACT2030
RALEIGH, N.C., Feb. 12, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce that it has joined IMPACT2030 as a collaborating partner. IMPACT2030 is a coalition of businesses working in partnership to help achieve...
Jan 24, 2018 04:55 pm ET
PRA Health Sciences to Report Fourth Quarter 2017 Earnings
RALEIGH, N.C., Jan. 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2017 results after the market closes on Wednesday, February 21, 2018. The Company will also host a...
Jan 16, 2018 10:00 am ET
PRA Health Sciences Opens New Salt Lake City Clinic
RALEIGH, N.C., Jan. 16, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce the opening of a new clinic in Salt Lake City, Utah. The new facility will offer full service early stage clinical...
Nov 06, 2017 07:50 am ET
Report: Developing Opportunities within Abaxis, PRA Health Sciences, Brighthouse, Investors Bancorp, Cypress Semiconductor, and Sage Therapeutics – Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 06, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abaxis, Inc. (NASDAQ:ABAX), PRA Health Sciences,...
Oct 24, 2017 11:00 am ET
Care Innovations® and PRA Health Sciences Announce Strategic Partnership
As part of Care Innovations® focus on expanding into adjacent markets, the company is proud to announce its exclusive global partnership with PRA Health Sciences (NASDAQ:PRAH). PRA is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries.
Aug 14, 2017 04:05 pm ET
PRA Health Sciences Announces Appointment of New Director
RALEIGH, N.C., Aug. 14, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Alexander G. Dickinson to the Board of Directors of the Company....
Aug 08, 2017 04:43 pm ET
PRA Health Sciences, Inc. Announces Secondary Offering of 10,000,000 Shares of Common Stock
RALEIGH, N.C., Aug. 08, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders, including an affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts & Co. (the “Selling Stockholders”), intend to offer for sale in an underwritten secondary offering 10,000,000 shares of common stock of the Company pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission. The Selling Stockholders will receive all of the proceeds from this offering. No shares are being sold by th...
Jul 25, 2017 04:05 pm ET
PRA Health Sciences to Report 2nd Quarter 2017 Earnings
RALEIGH, N.C., July 25, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter results after the market closes on Monday, August 7, 2017. The Company will also host a conference call on Tuesday, August 8 at 9:00 a.m. (ET) to discuss the results with members of the investment community....
May 11, 2017 09:30 am ET
DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM)
VANCOUVER, British Columbia and MENLO PARK, Calif., May 11, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing new cancer therapies, today announced the formalization of an agreement with PRA Health Sciences (Nasdaq: PRAH), a leading contract research organization (CRO) to conduct the Company's Phase 3 trial of VAL-083 in recurrent glioblastoma multiforme (GBM).
Apr 25, 2017 04:00 pm ET
PRA Health Sciences, Inc. Reports First Quarter 2017 Results
Net new business of $564.8 million in the first quarter; Net book-to-bill of 1.32$427.1 million of service revenue in the first quarter; 14.7% growth at actual foreign exchange rates and 15.1% constant currency growth compared to the first quarter of 2016First quarter GAAP Net Income per diluted share was $0.39 and GAAP Net Income was $25.2 million First quarter Adjusted Net Income per diluted share was $0.62 per share and Adjusted Net Income was $40.4 millionReaffirming full year 2017 service revenue guidance between $1.795 billion and $1.835 billion, GAAP net income per diluted share between...
Apr 17, 2017 04:12 pm ET
PRA Health Sciences to Report First Quarter 2017 Earnings
RALEIGH, N.C., April 17, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2017 results after the market closes on Tuesday, April 25, 2017. The Company will also host a conference call on Wednesday, April 26, 2017 at 9:00 a.m. (ET) to discuss the results and guidance with members of the investment community....
Mar 27, 2017 09:00 am ET
PRA Health Sciences Named Top Workplace in Philadelphia
RALEIGH, N.C., March 27, 2017 (GLOBE NEWSWIRE) -- For the second year in a row, PRA Health Sciences (PRA) (NASDAQ:PRAH), a leading global contract research organization, has been awarded a Top Workplaces honor by Philly.com....
Feb 22, 2017 04:00 pm ET
PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2016 Results and Provides Q1 and Full Year 2017 Guidance
Net new business of $587.3 million in the fourth quarter; Net book-to-bill of 1.42 $413.6 million of service revenue in the fourth quarter; 14.2% growth at actual foreign exchange rates and 14.6% constant currency growth compared to the fourth quarter of 2015 Fourth quarter GAAP Net Income per diluted share was $0.22 and GAAP Net Income was $14.0 million  Fourth quarter Adjusted Net Income per diluted share was $0.71 per share and Adjusted Net Income was $45.9 million RALEIGH, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA” or the “Company”) (NASDAQ:PRAH) today repo...
Feb 02, 2017 04:48 pm ET
PRA Health Sciences to Report Fourth Quarter 2016 Earnings and Issue 2017 Guidance
RALEIGH, N.C., Feb. 02, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2016 results and issue 2017 guidance after the market closes on Wednesday, February 22, 2017. The Company will also host a conference call on Thursday, February 23, 2017 at 9:00 a.m. (ET) to discuss the results and guidance with members of the investment community....
Nov 10, 2016 04:25 pm ET
PRA Health Sciences, Inc. Announces Secondary Offering of 7,500,000 Shares of Common Stock
RALEIGH, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that one of its stockholders, consisting of an affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts & Co. (the “Selling Stockholder”), intends to offer for sale in an underwritten secondary offering 7,500,000 shares of common stock of the Company pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission. The Selling Stockholder will receive all of the proceeds from this offering. No shares are being sold by the ...
Oct 10, 2016 03:46 pm ET
PRA Health Sciences to Report Third Quarter 2016 Earnings
RALEIGH, N.C., Oct. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2016 results after the market closes on Wednesday, November 2. The Company will also host a conference call on Thursday, November 3 at 9:00 a.m. (ET) to discuss the results with members of the investment community....
Jul 28, 2016 04:00 pm ET
PRA Health Sciences, Inc. Reports Second Quarter 2016 Results
$394.2 million of service revenue in the second quarter; 17.3% constant currency growth compared to the second quarter of 2015Second quarter GAAP Net Income per diluted share increased 200.0% to $0.60 per diluted share and GAAP Net Income increased 211.5% to $38.7 million compared to the second quarter of 2015$73.3 million of Adjusted EBITDA in the second quarter; 19.6% growth compared to the second quarter of 2015Second quarter Adjusted Net Income per diluted share increased 34.0% to $0.63 per share and Adjusted Net Income increased 36.3% to $40.5 million compared to the second quarter of 2...
Jul 18, 2016 06:08 pm ET
PRA Health Sciences to Report Second Quarter 2016 Earnings
RALEIGH, N.C., July 18, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter 2016 results after the market closes on Thursday, July 28. The Company will also host a conference call on Friday, July 29 at 9:00 a.m. (ET) to discuss the results with members of the investment community....
May 17, 2016 04:00 am ET
PRA Health Sciences Named International Clinical Research Company of the Year
RALEIGH, N.C., May 17, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce that for the third consecutive year it was recognized as the Clinical Research Company of the Year. PRA received the award at the PharmaTimes International Clinical Researcher of the Year ceremony in London. This award follows PRA’s recent recognition as Clinical Research Company of the Year in the PharmaTimes Americas competition where PRA captured six individual awards, including two gold (Experienced CRA and Strategic Partnership—PRA and CytRx)....
May 02, 2016 04:55 pm ET
PRA Health Sciences, Inc. Announces Secondary Offering of 5,000,000 Shares of Common Stock
RALEIGH, N.C., May 02, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders (the “Selling Stockholders”), intend to offer for sale in an underwritten secondary offering 5,000,000 shares of common stock of the Company pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission. The Selling Stockholders will receive all of the proceeds from this offering. No shares are being sold by the Company. The last reported sale price of the Company’s common stock on May 2, 2016 was...
Apr 27, 2016 04:00 pm ET
PRA Health Sciences, Inc. Reports First Quarter 2016 Results and Updates 2016 Guidance
$372.3 million of service revenue in the first quarter; 13.0% constant currency growth compared to the first quarter of 2015 First quarter GAAP Net Loss of $16.0 million or $0.27 per diluted share, which includes $28.9 million of one-time transaction-related costs and a $21.5 million loss from the completion of our Senior Note tender offer $67.4 million of Adjusted EBITDA in the first quarter; 20.8% growth compared to the first quarter of 2015 First quarter Adjusted Net Income per diluted share increased 34.1% to $0.55 per share and Adjusted Net Income increased 35.2% to $34.9 million co...
Apr 25, 2016 10:00 am ET
CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year
LOS ANGELES, April 25, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that two members of its clinical development team, Scott Wieland, Ph.D., Senior Vice President, Drug Development, and Nancy Wu, Senior Director of Clinical Operations, received the prestigious gold award at the PharmaTimes Clinical Researcher of the Year – The Americas competition held in Atlanta, Georgia.  The award in the Strategic Partnership Team category is shared with CytRx's partners at PRA Health Sciences, Inc., (

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.